can glp 1 cause body aches Shed Experiencing Side Effects from GLP-1

GLP-1 (short for glucagon-like peptide-1 ) medications have transformed the way we approach sustainable, long-term weight loss in todays world

Similar to the results in the breast cancer cell lines, the liraglutide treatment produced significant demethylation in CDH1 and ADAM33 promoter regions

doi: 10.1038/pr.2014.156 89 SgourasDNPanayotopoulouEGMartinez-GonzalezBPetrakiKMichopoulosSMentisA

Weight Loss Plateaus Are Normal and Seen in Every Major GLP-1/GIP Study The Standard Weight-Loss Curve Clinical trials consistently show that weight loss with GLP-1 and GLP-1/GIP medications follows a predictable pattern: Rapid weight loss early Gradual slowing over time A plateau phase where weight stabilizes This pattern has been observed across: Semaglutide trials ( STEP program ) Tirzepatide trials ( SURMOUNT-1 , SURMOUNT-4 ) Long-term cardiovascular outcomes studies ( SELECT ) In these studies, most participants lost weight more rapidly during the first several months, then experienced a gradual slowing and reached their average maximum weight loss around 918 months , after which weight tended to stabilize rather than continue to drop indefinitely

While sweet smell or taste of urine is a classical and historical sign of diabetes, fasting plasma glucose (FPG), oral glucose tolerance test (OGTT), glycated hemoglobin A1c (HbA1c), insulin, and C-peptide levels are currently used to examine functional pancreas

Although there is strong evidence supporting the benefit of GLP-1RAs in populations with obesity, their efficacy in other populations of particular HF subtypes and specific cardiomyopathies is unclear